Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis

Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis

Authors

  • Dario Buononato Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy
  • Gaetano Licata Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy
  • Alessio Gambardella Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy
  • Alina De Rosa Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy
  • Giulia Calabrese Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy
  • Giuseppe Argenziano Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli, Naples, Italy

Keywords:

tildrakizumab, psoriatic arthritis, psoriasis, psoriasis treatment

References

1. Nguyen CT, Bloch Y, Składanowska K, et al. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clin Immunol. 2019 Sep; 206:15-22. doi: 10.1016/j.clim.2018.09.002. Epub 2018 Sep 6. PMID: 30196070; PMCID: PMC6401348.
2. Boehncke WH, Brembilla NC, Nissen MJ. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. Expert Rev Clin Immunol. 2021 Jan;17(1):5-13. doi: 10.1080/1744666X.2020.1857733. Epub 2020 Dec 7. PMID: 33251833.

Downloads

Published

2022-05-02

Issue

Section

Research Letter

How to Cite

1.
Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis. Dermatol Pract Concept [Internet]. 2022 May 2 [cited 2024 Mar. 29];12(2):e2022049. Available from: https://dpcj.org/index.php/dpc/article/view/1879